

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

TECHNE CORP /MN/
Form 10-Q
November 08, 2006

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2006, or

() TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 0-17272

TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

MINNESOTA
(State or other jurisdiction of
incorporation or organization)

41-1427402
(I.R.S. Employer
Identification No.)

614 MCKINLEY PLACE N.E.
MINNEAPOLIS, MN 55413
(Address of principal
executive offices) (Zip Code)

(612) 379-8854
(Registrant's telephone number,
including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No ()

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Securities Exchange Act.

Large accelerated filer (X) Accelerated filer () Non-accelerated filer ()

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). () Yes (X) No

At November 3, 2006, 39,376,782 shares of the Company's Common Stock (par value \$.01) were outstanding.

TECHNE CORPORATION
FORM 10-Q

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

SEPTEMBER 30, 2006

INDEX

| | PAGE NO. |
|--|----------|
| PART I. FINANCIAL INFORMATION | |
| ITEM 1. FINANCIAL STATEMENTS (unaudited) | |
| Condensed Consolidated Balance Sheets as of September 30, 2006 and June 30, 2006 | 3 |
| Condensed Consolidated Statements of Earnings for the Quarters Ended September 30, 2006 and 2005 | 4 |
| Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2006 and 2005 | 5 |
| Notes to Condensed Consolidated Financial Statements | 6 |
| ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 10 |
| ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 15 |
| ITEM 4. CONTROLS AND PROCEDURES | 16 |
| PART II. OTHER INFORMATION | |
| ITEM 1. LEGAL PROCEEDINGS | 16 |
| ITEM 1A. RISK FACTORS | 16 |
| ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 17 |
| ITEM 3. DEFAULTS UPON SENIOR SECURITIES | 17 |
| ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SHAREHOLDERS | 17 |
| ITEM 5. OTHER INFORMATION | 18 |
| ITEM 6. EXHIBITS | 18 |
| SIGNATURES | 18 |

2

PART I. FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)

9/30/06 6/30/06

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | |
|--|-----------|-----------|
| ASSETS | | |
| Cash and cash equivalents | \$ 97,827 | \$ 89,634 |
| Short-term available-for-sale investments | 22,704 | 19,212 |
| Trade accounts receivable, net | 24,466 | 23,769 |
| Other receivables | 1,218 | 1,309 |
| Inventories | 8,982 | 9,024 |
| Deferred income taxes | 6,436 | 6,121 |
| Prepaid expenses | 850 | 753 |
| | ----- | ----- |
| Total current assets | 162,483 | 149,822 |
| Available-for-sale investments | 76,596 | 77,660 |
| Property and equipment, net | 89,418 | 88,772 |
| Goodwill, net | 25,308 | 25,308 |
| Intangible assets, net | 6,310 | 6,713 |
| Deferred income taxes | 4,420 | 4,638 |
| Investments | 24,305 | 17,195 |
| Other assets | 365 | 404 |
| | ----- | ----- |
| | \$389,205 | \$370,512 |
| | ===== | ===== |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Trade accounts payable | \$ 3,607 | \$ 3,627 |
| Salaries, wages and related accruals | 2,909 | 5,148 |
| Other accounts payable and accrued expenses | 2,207 | 1,833 |
| Income taxes payable | 5,650 | 6,129 |
| Current portion of long-term debt (Note G) | 13,135 | 1,229 |
| | ----- | ----- |
| Total current liabilities | 27,508 | 17,966 |
| Long-term debt, less current portion | -- | 12,198 |
| | ----- | ----- |
| Total liabilities | 27,508 | 30,164 |
| | ----- | ----- |
| Commitments and contingencies | | |
| Common stock, par value \$.01 per share; | | |
| authorized 100,000,000; issued and outstanding | | |
| 39,380,782 and 39,376,782, respectively | 394 | 394 |
| Additional paid-in capital | 102,276 | 101,941 |
| Retained earnings | 251,960 | 232,328 |
| Accumulated other comprehensive income | 7,067 | 5,685 |
| | ----- | ----- |
| Total stockholders' equity | 361,697 | 340,348 |
| | ----- | ----- |
| | \$389,205 | \$370,512 |
| | ===== | ===== |

See notes to condensed consolidated financial statements.

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands, except per share data)
(unaudited)

QUARTER ENDED

9/30/06 9/30/05

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | |
|---|-----------|-----------|
| Net sales | \$52,351 | \$47,709 |
| Cost of sales | 11,237 | 11,096 |
| | ----- | ----- |
| Gross margin | 41,114 | 36,613 |
| | ----- | ----- |
| Operating expenses: | | |
| Selling, general and administrative | 7,067 | 6,454 |
| Research and development | 4,855 | 4,717 |
| Amortization of intangible assets | 403 | 492 |
| | ----- | ----- |
| Total operating expenses | 12,325 | 11,663 |
| | ----- | ----- |
| Operating income | 28,789 | 24,950 |
| | ----- | ----- |
| Other expense (income): | | |
| Interest expense | 268 | 223 |
| Interest income | (1,676) | (974) |
| Other, net | 485 | 211 |
| | ----- | ----- |
| Total other income | (923) | (540) |
| | ----- | ----- |
| Earnings before income taxes | 29,712 | 25,490 |
| Income taxes | 10,081 | 8,489 |
| | ----- | ----- |
| Net earnings | \$ 19,631 | \$ 17,001 |
| | ===== | ===== |
| | | |
| Earnings per share: | | |
| Basic | \$ 0.50 | \$ 0.44 |
| Diluted | \$ 0.50 | \$ 0.43 |
| | | |
| Weighted average common shares outstanding: | | |
| Basic | 39,379 | 38,754 |
| Diluted | 39,469 | 39,669 |

See notes to condensed consolidated financial statements.

4

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

| | QUARTER ENDED | |
|--|---------------|-----------|
| | 9/30/06 | 9/30/05 |
| | ----- | ----- |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Net earnings | \$ 19,631 | \$ 17,001 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | | |
| Depreciation and amortization | 1,665 | 1,723 |
| Deferred income taxes | (95) | (275) |
| Stock-based compensation expense | 165 | 270 |
| Excess tax benefit from stock option exercises | (24) | (1,210) |
| Losses by equity method investee | 127 | 82 |
| Other | 2 | 52 |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | |
|--|-----------|-----------|
| Change in operating assets and operating liabilities, net of acquisitions: | | |
| Trade accounts and other receivables | (443) | 61 |
| Inventories | (132) | 84 |
| Prepaid expenses | (94) | (16) |
| Trade, other accounts payable and accrued expenses | 88 | 523 |
| Salaries, wages and related accruals | (1,019) | (1,029) |
| Income taxes payable | (484) | 238 |
| | ----- | ----- |
| Net cash provided by operating activities | 19,387 | 17,504 |
| | ----- | ----- |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Additions to property and equipment | (1,899) | (752) |
| Purchase of available-for-sale investments | (4,275) | (16,265) |
| Proceeds from sales of available-for-sale investments | 1,234 | 6,520 |
| Proceeds from maturities of available-for-sale Investments | 1,320 | 2,940 |
| Increase in investments | (7,200) | -- |
| Acquisitions, net of cash acquired | -- | (19,587) |
| | ----- | ----- |
| Net cash used in investing activities | (10,820) | (27,144) |
| | ----- | ----- |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Issuance of common stock | 146 | 7,032 |
| Excess tax benefit from stock option exercises | 24 | 1,210 |
| Purchase of common stock for stock bonus plans | (1,222) | (1,292) |
| Payments on long-term debt | (292) | (300) |
| | ----- | ----- |
| Net cash (used in) provided by financing activities | (1,344) | 6,650 |
| | ----- | ----- |
| Effect of exchange rate changes on cash | 970 | (838) |
| | ----- | ----- |
| Net increase in cash and cash equivalents | 8,193 | (3,828) |
| Cash and cash equivalents at beginning of period | 89,634 | 80,344 |
| | ----- | ----- |
| Cash and cash equivalents at end of period | \$ 97,827 | \$ 76,516 |
| | ===== | ===== |

See notes to condensed consolidated financial statements.

5

TECHNE CORPORATION & SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

A. BASIS OF PRESENTATION:

The unaudited condensed consolidated financial statements of Techne Corporation and subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

A summary of significant accounting policies followed by the Company is

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

detailed in the Company's Annual Report on Form 10-K for fiscal 2006. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2006 included in the Company's Annual Report to Shareholders for fiscal 2006.

Recent Accounting Pronouncements:

In May 2005, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 154, Accounting Changes and Error Corrections. The Statement replaces APB Opinion No. 20, Accounting Changes and SFAS No. 3, Reporting Accounting Changes in Interim Financial Statements. SFAS No. 154 requires companies to apply voluntary changes in accounting principles retrospectively whenever practicable. The requirement is effective for the Company beginning in fiscal 2007. Adoption of the Statement did not have an impact on the Company's prior consolidated financial statements as it is prospective in nature.

In June 2006, the FASB issued Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109. FIN 48 requires disclosures of additional quantitative and qualitative information regarding uncertain tax positions taken for tax-return purposes that have not been recognized for financial reporting, along with analysis of significant changes during each period. The Interpretation is effective for the Company in fiscal 2008. The Company is currently evaluating the provisions of FIN 48, but it is not expected to have a material impact on the Company's consolidated financial statements.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. The Statement establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS No. 157 applies only to fair value measurements that are already required or permitted by other accounting standards and is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 157, but it is not expected to have a material impact on the Company's consolidated financial statements.

In September 2006, the Securities and Exchange Commission released Staff Accounting Bulletin 108 (SAB 108). SAB 108 provides interpretative guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. SAB 108 is effective for the Company for fiscal year 2007. The Company is currently evaluating the impact of adopting SAB 108, but it is not expected to have a material impact on the Company's consolidated financial statements.

6

Certain consolidated balance sheet captions appearing in this interim report are as follows (in thousands):

| | 9/30/06 | 6/30/06 |
|--------------------------------------|-----------|-----------|
| | ----- | ----- |
| TRADE ACCOUNTS RECEIVABLE | | |
| Trade accounts receivable | \$ 24,588 | \$ 23,889 |
| Less allowance for doubtful accounts | 122 | 120 |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | |
|---|--------------------|--------------------|
| NET TRADE ACCOUNTS RECEIVABLE | ----- \$ 24,466 | ----- \$ 23,769 |
| | ===== | ===== |
| INVENTORIES | | |
| Raw materials | \$ 3,703 | \$ 3,561 |
| Supplies | 127 | 119 |
| Finished goods | 5,152 | 5,344 |
| | ----- | ----- |
| TOTAL INVENTORIES | \$ 8,982 | \$ 9,024 |
| | ===== | ===== |
| PROPERTY AND EQUIPMENT | | |
| Land | \$ 4,214 | \$ 4,214 |
| Buildings and improvements | 88,237 | 88,399 |
| Building construction in progress | 11,538 | 9,965 |
| Laboratory equipment | 19,727 | 19,473 |
| Office equipment | 3,923 | 3,711 |
| Leasehold improvements | 853 | 843 |
| | ----- | ----- |
| | 128,492 | 126,605 |
| Less accumulated depreciation and amortization | 39,074 | 37,833 |
| | ----- | ----- |
| NET PROPERTY AND EQUIPMENT | \$ 89,418 | \$ 88,772 |
| | ===== | ===== |
| GOODWILL | \$ 51,614 | \$ 51,614 |
| Less accumulated amortization | 26,306 | 26,306 |
| | ----- | ----- |
| NET GOODWILL | \$ 25,308 | \$ 25,308 |
| | ===== | ===== |
| INTANGIBLE ASSETS | | |
| Customer relationships | \$ 20,200 | \$ 20,200 |
| Technology | 4,213 | 4,213 |
| Trade names and trademarks | 1,396 | 1,396 |
| Supplier relationships | 14 | 14 |
| | ----- | ----- |
| | 25,823 | 25,823 |
| Less accumulated amortization | 19,513 | 19,110 |
| | ----- | ----- |
| NET INTANGIBLE ASSETS | \$ 6,310 | \$ 6,713 |
| | ===== | ===== |
| ACCUMULATED OTHER COMPREHENSIVE INCOME: | | |
| Foreign currency translation adjustments | \$ 7,327 | \$ 6,521 |
| Unrealized losses on available-for-sale investments | (260) | (836) |
| | ----- | ----- |
| TOTAL ACCUMULATED OTHER COMPREHENSIVE INCOME | \$ 7,067 | \$ 5,685 |
| | ===== | ===== |

7

B. EARNINGS PER SHARE:

Shares used in the earnings per share computations are as follows (in thousands):

| | QUARTER ENDED | |
|--|---------------|---------|
| | 9/30/06 | 9/30/05 |
| | ----- | ----- |
| Weighted average common shares outstanding-basic | 39,379 | 38,754 |
| Dilutive effect of forward contract | -- | 489 |
| Dilutive effect of stock options and warrants | 90 | 426 |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | | |
|--|--------|--------|
| | ----- | ----- |
| Weighted average common shares outstanding-diluted | 39,469 | 39,669 |
| | ===== | ===== |

The dilutive effect of stock options and warrants in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 37,000 and 78,000 for the quarters ended September 30, 2006 and 2005, respectively.

The forward contract in the above table refers to the accelerated stock buyback ("ASB") transaction settled in December 2005. In March 2005, the Company repurchased approximately 2.9 million shares of its common stock under an accelerated stock buyback ("ASB") transaction for an initial value of approximately \$100 million (\$34.45 per share). The transaction was completed under a privately negotiated contract with an investment bank. The investment bank borrowed the 2.9 million shares to complete the transaction and purchased the replacement shares in the open market over a nine-month period beginning in March 2005. The ASB agreement was subject to a market price adjustment provision based upon the volume weighted average price during the nine-month period. The Company had the option to settle the ASB agreement in cash or shares of the Company's common stock (forward contract) and, accordingly the contract was classified as equity. The ASB agreement was settled in December 2005 for a cash payment of \$26.0 million, which resulted in a total price paid per share of approximately \$44.67.

C. SEGMENT INFORMATION:

The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R&D Systems Europe and hematology. The biotechnology segment consists of R&D Systems' Biotechnology Division, Fortron Bio Science, Inc. and BiosPacific, Inc., which develop, manufacture and sell biotechnology research and diagnostic products world-wide. R&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale world-wide.

Following is financial information relating to the Company's operating segments (in thousands):

| | QUARTER ENDED | |
|------------------------------------|---------------|-----------|
| | 9/30/06 | 9/30/05 |
| | ----- | ----- |
| External sales | | |
| Biotechnology | \$ 35,922 | \$ 32,300 |
| R&D Systems Europe | 12,927 | 11,875 |
| Hematology | 3,502 | 3,534 |
| | ----- | ----- |
| Total external sales | 52,351 | 47,709 |
| Intersegment sales - Biotechnology | 5,699 | 5,299 |
| | ----- | ----- |
| Total sales | 58,050 | 53,008 |
| Less intersegment sales | (5,699) | (5,299) |
| | ----- | ----- |
| Total consolidated net sales | \$52,351 | \$47,709 |
| | ===== | ===== |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | QUARTER ENDED | |
|------------------------------------|---------------|-----------|
| | 9/30/06 | 9/30/05 |
| Earnings before income taxes | | |
| Biotechnology | \$ 24,468 | \$ 20,758 |
| R&D Systems Europe | 5,350 | 4,800 |
| Hematology | 907 | 897 |
| Corporate and other | (1,013) | (965) |
| Total earnings before income taxes | \$ 29,712 | \$ 25,490 |

D. STOCK OPTIONS:

Option activity under the Company's stock option plans during the three months ended September 30, 2006 were as follows:

| | SHARES (in 000's) | WEIGHTED AVG. EXERCISE PRICE | WEIGHTED AVG. CONTRACTUAL LIFE (Yrs.) | AGGREGATE INTRINSIC VALUE |
|-----------------------------------|----------------------|---------------------------------------|--|---------------------------------|
| Outstanding at June 30, 2006 | 421 | \$38.89 | | |
| Granted | 3 | 49.43 | | |
| Exercised | (4) | 36.50 | | |
| Forfeited or expired | -- | -- | | |
| Outstanding at September 30, 2006 | 420 | 38.99 | 4.58 | \$5.2 million |
| Exercisable at September 30, 2006 | 381 | \$38.50 | 4.33 | \$4.9 million |

The fair value of options granted under the Company's stock option plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

| | QUARTER ENDED | |
|---|---------------|-----------|
| | 9/30/06 | 9/30/05 |
| Dividend yield | -- | -- |
| Expected annualized volatility | 31%-35% | 37%-53% |
| Risk free interest rate | 4.9%-5.1% | 4.0%-4.1% |
| Expected life | 4-5 years | 4-6 years |
| Weighted average fair value of options granted | \$18.29 | \$25.22 |

The Company has not paid cash dividends and does not have any plans to do so, therefore an expected dividend yield of zero was used to estimate fair value of options granted. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted. Separate groups of employees that have similar historical exercise behavior with regard to option exercise timing and forfeiture rates are considered separately in determining option fair value.

The total intrinsic value of options exercised during the quarters ended September 30, 2006 and 2005 were \$55,000 and \$5.2 million, respectively.

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

Stock option exercises are satisfied through the issuance of new shares. The total fair value of options vested during the quarters ended September 30, 2006 and 2005 were \$57,000 and \$58,000, respectively.

9

Stock-based compensation cost of \$165,000 and \$270,000 was included in selling, general and administrative expense for the quarters ended September 30, 2006 and 2005, respectively. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. As of September 30, 2006, there was \$259,000 of total unrecognized compensation cost related to nonvested stock options which will be expensed over fiscal years 2007 through 2009.

E. COMPREHENSIVE INCOME:

Comprehensive income and the components of other comprehensive income (loss) were as follows (in thousands):

| | QUARTER ENDED | |
|--|---------------|-----------|
| | 9/30/06 | 9/30/05 |
| Net earnings | \$ 19,631 | \$ 17,001 |
| Other comprehensive gain (loss), net of tax effect: | | |
| Foreign currency translation adjustments | 806 | (889) |
| Unrealized gain (loss) on available- for-sale investments | 576 | (76) |
| Comprehensive income | \$ 21,013 | \$ 16,036 |

F. INVESTMENTS:

In September 2006, the Company invested \$7.2 million for an 18% equity interest in Nephromics, LLC. Nephromics has licensed technology related to the diagnosis of preeclampsia and has sub-licensed the technology to several major diagnostic companies for the development of diagnostic assays.

G. SUBSEQUENT EVENT:

On October 31, 2006, the Company paid off its mortgage debt. The total payment of \$13.8 million included the mortgage principle balance, accrued interest and a 5% prepayment penalty of \$652,000. As a result of the payment, the mortgage was included in current liabilities as of September 30, 2006.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations for the Quarter Ended September 30, 2006
and the Quarter Ended September 30, 2005

Overview

TECHNE Corporation (the Company) has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) and R&D Systems Europe Ltd. (R&D Europe). R&D Systems, located in Minneapolis, Minnesota, has two divisions:

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

its Biotechnology Division and its Hematology Division. The Biotechnology Division develops and manufactures purified cytokines (proteins), antibodies and assay kits which are sold to biomedical researchers and clinical research laboratories. The Hematology Division develops and manufactures whole blood hematology controls and calibrators which are sold to hospitals and clinical laboratories to check the performance of hematology instruments to assure the accuracy of hematology test results. R&D Systems has two subsidiaries: Fortron Bio Science, Inc., (Fortron) a developer and manufacturer of monoclonal and polyclonal antibodies, antigens and other biological reagents, located in Minneapolis and BiosPacific, Inc., (BiosPacific) a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems (IVDs) and immunodiagnostic kits, located in Emeryville, California. R&D Europe, located in Abingdon, England, is the European distributor of R&D Systems' biotechnology products. R&D Europe has a sales subsidiary, R&D Systems GmbH, in Germany and a sales office in France.

10

Overall Results

Consolidated net earnings increased 15.5% for the quarter ended September 30, 2006 compared to the quarter ended September 30, 2005. The primary reason for the increase was increased net sales and gross margins. Consolidated net sales for the quarter ended September 30, 2006 increased 9.7% from the same period in the prior year. The favorable impact on consolidated net sales of the change from the prior year in exchange rates used to convert R&D Europe results from British pound sterling to U.S. dollars was \$734,000 for the quarter ended September 30, 2006. The favorable impact on consolidated net earnings of the change in exchange rates was \$206,000 for the quarter ended September 30, 2006. The Company generated cash of \$19.4 million from operating activities in the first three months of fiscal 2007 and cash, cash equivalents and available-for-sale investments were \$197.1 million at September 30, 2006 compared to \$186.5 million at June 30, 2006.

Net Sales

Consolidated net sales for the quarter ended September 30, 2006 were \$52.4 million, an increase of \$4.6 million (9.7%) from the quarter ended September 30, 2005. Biotechnology net sales increased \$3.6 million (11.2%) for the quarter ended September 30, 2006, mainly as a result of \$2.6 million increased U.S. retail sales volume. Sales for the quarter to pharmaceutical/biotechnology customers and academic customers, the two largest segments of the U.S. market, showed the greatest revenue growth over the prior year. Approximately \$700,000 of the increase in biotechnology net sales for the quarter ended September 30, 2006 was the result of price increases.

R&D Europe net sales increased \$1.0 million (8.9%) for the quarter ended September 30, 2006 from the quarter ended September 30, 2005. The effect of changes from the prior year in foreign currency exchange rates used to convert British pounds to U.S. dollars increased R&D Europe net sales approximately \$734,000 for the quarter ended September 30, 2006. In British pounds, R&D Europe net sales increased 2.7% for the quarter ended September 30, 2006, mainly as a result of increased sales volume.

Hematology net sales decreased \$32,000 (.9%) for the quarter ended September 30, 2006 compared to the same prior-year period.

Gross Margins

Gross margins, as a percentage of net sales, were as follows:

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | QUARTER ENDED | |
|---------------------------|---------------|---------|
| | 9/30/06 | 9/30/05 |
| Biotechnology | 79.6% | 77.5% |
| R&D Systems Europe | 52.2% | 50.8% |
| Hematology | 40.1% | 40.4% |
| Consolidated gross margin | 78.5% | 76.7% |

Biotechnology gross margins as a percentage of sales for the quarter ended September 30, 2006 of 79.6% increased from the prior year mainly as a result of changes in product mix. Biotechnology gross margins were also affected by purchase accounting related to inventory on hand at the acquisition date of Fortron and BiosPacific in fiscal 2006. Included in cost of sales for the quarters ended September 30, 2006 and 2005 were \$291,000 and \$575,000, respectively related to inventory purchase accounting.

11

R&D Europe's gross margin percentages for the quarter ended September 30, 2006 were greater than the comparable prior-year period as a result of favorable exchange rates.

The Company values its manufactured protein and antibody inventory based on a two-year forecast. Quantities in excess of the two-year forecast are considered impaired and not included in the inventory value. Sales of previously impaired protein and antibody inventory for the quarters ended September 30, 2006 and 2005 were not material.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the quarter ended September 30, 2006, increased \$613,000 (9.5%) from the same period of last year. Selling, general and administrative expenses are composed of the following (in thousands):

| | QUARTER ENDED | |
|--|---------------|----------|
| | 9/30/06 | 9/30/05 |
| Biotechnology | \$ 4,013 | \$ 3,639 |
| R&D Europe | 2,020 | 1,782 |
| Hematology | 398 | 384 |
| Corporate | 636 | 649 |
| Total selling, general and administrative expenses | \$ 7,067 | \$ 6,454 |

Biotechnology selling, general and administrative expenses increased approximately \$374,000 (10.3%) for the quarter ended September 30, 2006, mainly due to a \$185,000 increase in wages and benefits as a result of additional sales, marketing and administrative personnel added since the prior year and a \$116,000 increase in profit sharing accrual from the prior year.

Research and Development Expenses

Research and development expenses are composed of the following (in thousands):

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| | QUARTER ENDED | |
|---|---------------|----------|
| | 9/30/06 | 9/30/05 |
| Biotechnology | \$ 4,675 | \$ 4,532 |
| Hematology | 180 | 185 |
| Total research and development expenses | \$ 4,855 | \$ 4,717 |

Other Non-operating Expense and Income

Other non-operating expense and income consists mainly of foreign currency transaction losses, rental income, building expenses related to rental property, and the Company's share of losses by Hemerus Medical, LLC (Hemerus).

| | QUARTER ENDED | |
|---|---------------|---------|
| | 9/30/06 | 9/30/05 |
| Foreign currency losses | \$ 147 | \$ 28 |
| Rental income | (299) | (342) |
| Real estate taxes, depreciation and utilities | 510 | 443 |
| Hemerus Medical, LLC losses | 127 | 82 |
| Total other non-operating expense (income) | \$ 485 | \$ 211 |

12

Through February 2006, the Company had a 10% equity interest in Hemerus. On March 1, 2006, the Company invested an additional \$750,000, increasing its ownership to 15%. At September 30, 2006, the Company's net investment in Hemerus was \$2.8 million. The Company accounts for its investment in Hemerus using the equity method of accounting as Hemerus is a limited liability corporation. The Company has financial exposure to the losses of Hemerus to the extent of its net investment in the company. Hemerus' success is dependent, in part, upon its ability to raise financing and to receiving Federal Drug Administration (FDA) clearance to market its products. If such financing or FDA clearance is not received, the Company would potentially recognize an impairment loss to the extent of its remaining net investment.

In September 2006, the Company invested \$7.2 million for an 18% equity interest in Nephromics, LLC (Nephromics). The Company accounts for its investment in Nephromics using the equity method of accounting as Nephromics is a limited liability corporation. At September 30, 2006, the Company's net investment in Nephromics was \$7.2 million. The Company has financial exposure to any losses of Nephromics to the extent of its net investment in the company.

Income Taxes

Income taxes for the quarters ended September 30, 2006 and 2005 were provided at rates of approximately 33.9% and 33.3%, respectively, of consolidated earnings before income taxes. U.S. federal taxes have been reduced by the credit for research and development expenditures through December 2005, the benefit for extraterritorial income and the manufacturer's deduction provided for under the American Jobs Creation Act of 2004. Foreign income taxes have been provided at rates which approximate the tax rates in the countries in

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

which R&D Europe operates. Without significant business developments, the Company expects income tax rates for the remainder of fiscal 2007 to range from 34% to 35%.

Liquidity and Capital Resources

At September 30, 2006, cash and cash equivalents and available-for-sale investments were \$197.1 million compared to \$186.5 million at June 30, 2006. The Company believes it can meet its future cash, working capital and capital addition requirements through currently available funds, cash generated from operations and maturities of available-for-sale investments. The Company has an unsecured line of credit of \$750,000. The interest rate on the line of credit is at prime. There were no borrowings on the line in the prior or current fiscal year.

Cash Flows From Operating Activities

The Company generated cash of \$19.4 million from operating activities in the first three months of fiscal 2007 compared to \$17.5 million in the first three months of fiscal 2006. The increase from the prior year was mainly the result of increased net earnings in the current year of \$2.6 million.

Cash Flows From Investing Activities

Capital expenditures for fixed assets for the first three months of fiscal 2007 and 2006 were \$1.9 million and \$752,000, respectively. Included in capital expenditures for the first three months of fiscal 2007 were \$1.6 million for building renovation and construction. The remaining capital additions in the first three months of fiscal 2007 and 2006 were for laboratory and computer equipment. Remaining expenditures in fiscal 2007 for laboratory and computer equipment are expected to be approximately \$4.5 million. The Company is currently constructing additional laboratory space at its Minneapolis facility. The remaining construction cost is estimated at \$6.3 million and is expected to be complete in the fourth quarter of fiscal 2007. These expenditures are expected to be financed through currently available funds and cash generated from operating activities.

13

During the three months ended September 30, 2006, the Company purchased \$4.3 million and had sales or maturities of \$2.6 million of available-for-sale investments. During the three months ended September 30, 2005, the Company purchased \$16.3 million and had sales or maturities of \$9.5 million of available-for-sale investment. The Company's investment policy is to place excess cash in bonds and other investments with maturities of less than three years. The objective of this policy is to obtain the highest possible return with minimal risk, while keeping the funds accessible.

In September 2006, the Company invested \$7.2 million for an 18% equity interest in Nephromics, LLC. Nephromics has licensed technology related to the diagnosis of preeclampsia and has sub-licensed the technology to several major diagnostic companies for the development of diagnostic assays. The investment was financed through cash and equivalents on hand.

The Company acquired Fortron and BiosPacific effective July 1, 2005 for an aggregate purchase price of \$20 million. Cash acquired in the transactions was \$413,000. The net acquisition cost of \$19.6 million was financed through cash and equivalents on hand at July 1, 2005.

Cash Flows From Financing Activities

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

Cash of \$146,000 and \$7.0 million was received during the three months ended September 30, 2006 and 2005, respectively, for the exercise of stock options for 4,000 and 234,000 shares of common stock. The Company also recognized excess tax benefits from stock option exercises of \$24,000 and \$1.2 million for the three months ended September 30, 2006 and 2005, respectively.

In the first three months of fiscal 2007 and 2006, the Company purchased 22,400 shares and 22,541 shares of common stock, respectively, for its employee Stock Bonus Plans at a cost of \$1.2 million and \$1.3 million, respectively.

Subsequent to September 30, 2006, the Company paid off its mortgage debt. The total payment of \$13.8 million included the mortgage principle balance, accrued interest and a 5% prepayment penalty of \$652,000. Cash and equivalents on hand were used to settle the debt.

The Company has never paid cash dividends and has no plans to do so in fiscal 2007.

Critical Accounting Policies

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2006. The application of certain of these policies require judgments and estimates that can affect the results of operations and financial position of the Company. Judgements and estimates are used for, but not limited to, accounting for the allowance for doubtful accounts, inventory valuation and allowances, impairment of goodwill, intangibles and other long-lived assets, accounting for investments and income taxes. There have been no changes in estimates in fiscal 2007 which would require disclosure. There have been no changes to the Company's policies in fiscal 2007.

Recent Accounting Pronouncements

In May 2005, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 154, Accounting Changes and Error Corrections. The Statement replaces APB Opinion No. 20, Accounting Changes and SFAS No. 3, Reporting Accounting Changes in Interim Financial Statements. SFAS No. 154 requires companies to apply voluntary changes in accounting principles retrospectively whenever practicable. The requirement is effective for the Company beginning in fiscal 2007. Adoption of the Statement did not have an impact on the Company's prior consolidated financial statements as it is prospective in nature.

14

In June 2006, the FASB issued Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109. FIN 48 requires disclosures of additional quantitative and qualitative information regarding uncertain tax positions taken for tax-return purposes that have not been recognized for financial reporting, along with analysis of significant changes during each period. The Interpretation is effective for the Company in fiscal 2008. The Company is currently evaluating the provisions of FIN 48, but it is not expected to have a material impact on the Company's consolidated financial statements.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. The Statement establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS No. 157 applies only to fair value measurements that are already required or permitted by other accounting

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

standards and is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 157, but it is not expected to have a material impact on the Company's consolidated financial statements.

In September 2006, the Securities and Exchange Commission released Staff Accounting Bulletin 108 (SAB 108). SAB 108 provides interpretative guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. SAB 108 is effective for the Company for fiscal year 2007. The Company is currently evaluating the impact of adopting SAB 108, but it is not expected to have a material impact on the Company's consolidated financial statements.

Forward Looking Information and Cautionary Statements

This filing contains forward-looking statements within the meaning of the Private Litigation Reform Act. These statements, including the Company's expectations as to compensation expense resulting from stock option expensing, the effective tax rate and capital equipment expenditures, involve risks and uncertainties which may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM (private label) and proficiency survey business, the impact of currency exchange rate fluctuations, the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships, and the success of financing efforts by companies in which the Company has invested. For additional information concerning such factors, see the Company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At September 30, 2006, the Company had a professionally managed investment portfolio of fixed income securities, excluding those classified as cash and cash equivalents, of \$99.0 million. These securities, like all fixed income instruments, are subject to interest rate risk and will decline in value if market interest rates increase.

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency rate changes. The Company is exposed to market risk from foreign exchange rate fluctuations of the euro and the British pound to the U.S. dollar as the financial position and operating results of the Company's U.K. subsidiary and European operations are translated into U.S. dollars for consolidation. At the current level of R&D Europe operating results, a 10% increase or decrease in the average exchange rate used to translate operating results into U.S. dollars would have an approximate \$1.5 million effect on consolidated operating income annually.

The Company's exposure to foreign exchange rate fluctuations also arises from transferring funds from the U.K. subsidiary to the U.S. subsidiary and from transferring funds from the German subsidiary and French sales office to the U.K. subsidiary. At September 30, 2006 and 2005, the Company had \$540,000 and \$352,000, respectively, of dollar denominated intercompany debt at its U.K. subsidiary. At September 30, 2006 and 2005, the U.K. subsidiary had \$345,000

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

and \$495,000, respectively, of dollar denominated intercompany debt from its European operations. These intercompany balances are revolving in nature and are not deemed to be long-term balances. The Company's U.K. subsidiary recognized net foreign currency losses of 78,000 British pounds (\$147,000) and 15,000 British pounds (\$28,000) for the quarters ended September 30, 2006 and 2005, respectively. The Company does not enter into foreign exchange forward contracts to reduce its exposure to foreign currency rate changes on intercompany foreign currency denominated balance sheet positions.

As of September 30, 2006, the Company's long-term debt of \$13.1 million consisted of a mortgage note payable with a floating interest rate at the one-month LIBOR rate plus 2.5% with a floor of 4%. The floating interest rate on the mortgage note payable was 7.8% as of September 30, 2006. On October 31, 2006, the Company paid off its mortgage debt.

ITEM 4 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the Company conducted an evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")). Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. There was no changes in the Company's internal control over financial reporting during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

See Item 3 of the Registrant's Annual Report of Form 10-K for the fiscal year ended June 30, 2006.

ITEM 1A. - RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2006.

16

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table sets forth the repurchases of Company common stock for the quarter ended September 30, 2006:

| Total Number of Shares Purchased as | Maximum Approximate Dollar Value of |
|--|--|
|--|--|

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| Period | Total Number of Shares Purchased | Average Price Paid Per Share | Part of Publicly Announced Plans or Programs | Shares that May Yet Be Purchased Under the Plans or Programs |
|---------------------|--|------------------------------------|--|--|
| 7/1/06 - 7/31/06 | 0 | -- | 0 | \$6.8 million |
| 8/1/06 - 8/31/06 | 0 | -- | 0 | \$6.8 million |
| 9/1/06 - 9/30/06 | 22,440 | \$50.07 | 0 | \$6.8 million |

In May 1995, the Company announced a plan to purchase and retire its common stock. Repurchases of \$40 million were authorized as follows: May 1995 - \$5 million; April 1997 - \$5 million; January 2001 - \$10 million; October 2002 - \$20 million. The plan does not have an expiration date.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - SUBMISSION OF MATTERS TO VOTE OF SHAREHOLDERS

- a. The Annual Meeting of the Registrant's shareholders was held on Thursday, October 26, 2006.
- b. A proposal to set the number of directors at seven was adopted by a vote of 36,642,683 in favor with 105,982 shares against, and 20,137 shares abstaining. No shares represented broker nonvotes.
- c. Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934. There was no solicitation in opposition to management's nominees as listed in the Proxy Statement, and all such nominees were elected as follows:

| Nominee | For | Withheld |
|-----------------------|------------|-----------|
| Thomas E. Oland | 36,243,405 | 525,368 |
| Roger C. Lucas | 34,628,305 | 2,140,468 |
| Howard V. O'Connell | 35,217,519 | 1,551,254 |
| G. Arthur Herbert | 36,006,081 | 762,692 |
| Randolph C. Steer | 35,997,656 | 771,117 |
| Robert V. Baumgartner | 36,019,356 | 749,417 |
| Charles A. Dinarello | 36,635,006 | 133,767 |

17

ITEM 5 - OTHER INFORMATION

None.

ITEM 6 - EXHIBITS

See exhibit index following.

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TECHNE CORPORATION
(Company)

Date: November 8, 2006

/s/ Thomas E. Oland

President, Chief Executive Officer

November 8, 2006

/s/ Gregory J. Melsen

Chief Financial Officer

EXHIBIT INDEX
TO
FORM 10-Q

TECHNE CORPORATION

| Exhibit # | Description |
|-----------|---------------------------|
| 31.1 | Section 302 Certification |
| 31.2 | Section 302 Certification |
| 32.1 | Section 906 Certification |
| 32.2 | Section 906 Certification |